These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8761361)

  • 1. Meta-analyses of randomised trials: when the whole is more than just the sum of the parts.
    Parmar MK; Stewart LA; Altman DG
    Br J Cancer; 1996 Aug; 74(4):496-501. PubMed ID: 8761361
    [No Abstract]   [Full Text] [Related]  

  • 2. [Carboplatin in cancer of the ovary].
    Pujade-Lauraine E; Guastalla JP; Vincent P
    Bull Cancer; 2000 Aug; 87 Spec No():40-7. PubMed ID: 11082722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.
    BMJ; 1991 Oct; 303(6807):884-93. PubMed ID: 1834291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.
    Aabo K; Adams M; Adnitt P; Alberts DS; Athanazziou A; Barley V; Bell DR; Bianchi U; Bolis G; Brady MF; Brodovsky HS; Bruckner H; Buyse M; Canetta R; Chylak V; Cohen CJ; Colombo N; Conte PF; Crowther D; Edmonson JH; Gennatas C; Gilbey E; Gore M; Guthrie D; Yeap BY
    Br J Cancer; 1998 Dec; 78(11):1479-87. PubMed ID: 9836481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platinums in lung cancer: sufficient or necessary?
    Bunn PA
    J Clin Oncol; 2005 May; 23(13):2882-3. PubMed ID: 15728220
    [No Abstract]   [Full Text] [Related]  

  • 6. Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer.
    Di Leo A; Buyse M
    J Clin Oncol; 2002 Apr; 20(7):1954-5. PubMed ID: 11919262
    [No Abstract]   [Full Text] [Related]  

  • 7. [First line chemotherapy for advanced ovarian cancer in 2000: standards and questions].
    Cure H; Dauplat J; Cholet P
    Bull Cancer; 2000 Feb; 87(2):189-99. PubMed ID: 10705290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
    Ost E; Illiger HJ
    Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
    [No Abstract]   [Full Text] [Related]  

  • 9. Platinum compounds in the treatment of advanced breast cancer.
    Martín M
    Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study.
    Lancet; 1998 Nov; 352(9140):1571-6. PubMed ID: 9843101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose intensity in advanced ovarian cancer: have we answered the question?
    Fennelly D
    Clin Cancer Res; 1995 Jun; 1(6):575-82. PubMed ID: 9816018
    [No Abstract]   [Full Text] [Related]  

  • 12. [Sequencing of adjuvant treatment after surgery for invasive breast cancer].
    Petit T; Claude L; Carrie C
    Cancer Radiother; 2004 Feb; 8(1):54-8. PubMed ID: 15093202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy with CEF versus CMF for node-positive breast cancer.
    Atkins CD
    J Clin Oncol; 1998 Dec; 16(12):3916-7. PubMed ID: 9850039
    [No Abstract]   [Full Text] [Related]  

  • 14. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
    Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
    Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy in breast cancer: back to the future.
    Colleoni M; Goldhirsch A
    Onkologie; 2003 Apr; 26(2):111-2. PubMed ID: 12771517
    [No Abstract]   [Full Text] [Related]  

  • 16. Wide-field radiation as adjunct to adjuvant chemotherapy in high-risk cases with early breast cancer: do it or not?
    Ragaz J; Spinelli JJ
    Int J Cancer; 2000 Aug; 87(3):423-6. PubMed ID: 10897049
    [No Abstract]   [Full Text] [Related]  

  • 17. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of cisplatin and carboplatin versus cisplatin, vinblastine and bleomycin in ovarian cancer.
    Kikkawa F; Matsuzawa K; Arii Y; Kawai M; Kobayashi I; Nakashima N; Mizutani S
    Gynecol Obstet Invest; 2000; 50(4):269-74. PubMed ID: 11093052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Benefits of adjuvant chemotherapy for breast cancer].
    Motomura K; Noguchi S; Inaji H; Koyama H
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1239-44. PubMed ID: 9279342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Meta-analysis comparing cisplatin total dose intensity and survival: a critical reappraisal.
    Sauerbrei W; Blettner M; Schumacher M
    Gynecol Oncol; 1996 Sep; 62(3):427-9. PubMed ID: 8830743
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.